Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company advancing targeted therapies for endocrine-driven breast cancers. This page provides investors and healthcare professionals with timely updates on clinical developments, financial disclosures, and strategic initiatives.
Access consolidated information about OLMA's lead candidate palazestrant (OP-1250), an oral complete estrogen receptor antagonist/SERD, and other pipeline assets like the KAT6 inhibitor OP-3136. Track regulatory milestones, partnership announcements, and peer-reviewed research findings in one centralized location.
Key updates include clinical trial progress, scientific conference presentations, and financial results. All content is sourced from official company communications and verified industry reports to ensure accuracy.
Bookmark this page for streamlined access to OLMA's latest developments in women's oncology therapeutics. Check regularly for essential updates impacting treatment innovation and corporate strategy.
On June 9, 2022, Olema Pharmaceuticals (Nasdaq: OLMA) announced an exclusive global license agreement with Aurigene Discovery Technologies to develop small molecule inhibitors targeting an undisclosed oncology target. Olema will pay an upfront fee of $8 million, with Aurigene eligible for up to $60 million in clinical milestones and $370 million in commercial milestones. Olema aims to enhance its drug discovery portfolio while maintaining adequate funding for research and development through 2024. This collaboration underscores Olema's focus on cancer treatments for women, particularly with its lead candidate, OP-1250.
On June 2, 2022, Olema Pharmaceuticals granted stock options for 25,400 shares to two new employees under its 2022 Inducement Plan. The options have a grant date of June 1, 2022, with a $2.80 exercise price, matching the last reported sale price. Vested over four years, 25% will vest on the first anniversary, followed by monthly installments. This decision complies with Nasdaq Listing Rule 5635(c)(4). Olema, focused on innovative cancer therapies, is currently evaluating OP-1250 in clinical trials for ER+ breast cancer.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, announced that CEO Sean P. Bohen will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 8:30 a.m. ET. The event will be accessible through a live webcast on Olema’s website, which will remain available for 14 days post-event.
Olema’s lead candidate, OP-1250, is undergoing clinical trials for treating ER-positive, HER2-negative breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) announced its Q1 2022 results, highlighting strong progress in clinical trials for its lead candidate, OP-1250. The Phase 1/2 trial continues to enroll patients, with the recommended Phase 2 dose expected by Q2 2022. The company has $267.9 million in cash, sufficient to fund operations into 2024. Despite a net loss of $23 million for the quarter—up from $15.3 million year-over-year—investments in OP-1250 are pivotal for growth. Olema plans to present updated clinical data later this year.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the granting of stock options for 68,700 shares to three new employees, effective May 2, 2022. The options were approved by the Compensation Committee and are part of the Company's 2022 Inducement Plan. They vest over four years, with an exercise price set at $2.68 per share, equal to the stock's last reported sale price. Olema focuses on targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for treating ER-positive breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) has granted a stock option to a new employee for 20,000 shares of its common stock as part of the 2022 Inducement Plan. The option, effective April 1, 2022, vests over four years, with 25% vesting after the first year and the remaining 75% in monthly installments. The exercise price is set at $4.10 per share, reflecting the last reported sale price on the grant date. This move aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting talent.
Olema Pharmaceuticals announced that its CEO, Sean P. Bohen, will participate in a virtual fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 11:30 a.m. ET. The event will be accessible via a live webcast on Olema’s website and archived for 14 days. Olema is focused on targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for ER-positive breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) announces plans to present two posters on nonclinical data for OP-1250 at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. The first presentation focuses on transcriptional changes in ER+ breast cancer cell lines in response to OP-1250, while the second highlights its efficacy in preventing tumor spread in metastatic ERα+ breast cancer models. OP-1250 is currently undergoing clinical trials in patients with advanced ER-positive breast cancer.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) reported significant progress in clinical studies for OP-1250, targeting ER+ / HER2- breast cancer. Phase 1a data showed favorable pharmacokinetics and encouraging anti-tumor activity in heavily pretreated patients. Enrollment for Phase 1b expansion is on track for completion in Q1 2022, with a Phase 2 study set to begin in H1 2022. The company's financial position is strong, with $287.3 million in cash, sufficient to fund operations into 2024, despite a net loss of $71.1 million for 2021, reflecting increased R&D and G&A expenses.
Olema Pharmaceuticals (Nasdaq: OLMA) announced that CEO Sean P. Bohen will present a corporate overview at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:50 p.m. ET. The presentation can be accessed via a live webcast on Olema's website and will be archived for 14 days. Olema Oncology focuses on developing targeted therapies for women’s cancers, with their lead product candidate, OP-1250, currently in Phase 1/2 trials for treating ER-positive breast cancer.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
